What Allodynia Tells us About Migraine: Q&A With David Dodick, MD, FAHS

How three factors associated with allodynia, as outlined by the MAST Study, affect migraine treatment options Allodynia is the experience when ordinarily nonpainful stimuli, like a light touch and brushing your hair, becomes painful. David Dodick, MD, FAHS, professor of neurology at the Mayo Clinic and Chair of the American Migraine Foundation, says 40% to 70% of people experience allodynia when having a migraine attack. We sat down with Dr. Dodick to discuss what we learned about allodynia from the Migraine in America Symptoms and Treatment (MAST) Study. https://www.youtube.com/watch?v=dvo4nNMPTVA Why is allodynia important and what can it tell us? Allodynia...

OnabotulinumtoxinA as a Treatment for Chronic Migraine

Carrie Dougherty, MD, FAHS, shares who is a suitable candidate and how providers can help patients access care Dr. Carrie Dougherty, Assistant Professor in the Department of Neurology and the Program Director of Headache Medicine Fellowship at MedStar Georgetown University Hospital, recently spoke on onabotulinumtoxinA as a potential treatment for patients with chronic migraine. Watch the full interview from the 2018 Scottsdale Headache Symposium here: https://www.youtube.com/watch?v=4ShnM_XgR9c OnabotA is different from other types of preventive treatments: It is a procedure that is administered every 12 weeks as an ongoing prevention method. The procedure is comprised of 31 injections located in the...

AHS Launches Position Statement about Integrating New Migraine Treatments Into Clinical Practice

The American Headache Society’s statement addresses the need for updated guidance on the preventive and acute treatment of migraine On December 10, 2018, the American Headache Society launched a position statement to provide healthcare professionals with updated guidance on the integration of novel preventive and acute treatments for migraine into clinical practice. Published in Headache, the paper demonstrates the ongoing commitment of the Society and its members to improving the lives of people with migraine in the ever-changing landscape of research, treatment, and education. The position statement was written to address the need for updated guidance on the preventive and...

American Migraine Foundation Facebook Live Round Up — December

Information and advice from fellow AHS members As a part of the #MoveAgainstMigraine campaign, the American Migraine Foundation invites members of the American Headache Society to host 30-minute Facebook Live events on their Facebook page. Each week, doctors share their expertise, answer questions and engage with patients and their supporters from all over the country. On behalf of AMF, thank you to all Society members who donated their time and shared their insights with the migraine community. Learn more about each of their discussions below: Clinical Pearls of Treating Migraine Larry Robbins, MD, Neurologist at the Robbins Headache Clinic, hosted...

American Migraine Foundation Facebook Live Round Up—November

Information from fellow members of AHS One of the primary goals of the American Headache Society is to promote the exchange of information concerning the causes, symptoms and treatments of headache and related painful disorders. As a professional society, we primarily focus on establishing opportunities for communication between health care professionals. However, our commitment to headache medicine includes our responsibility to educate patient communities. Over the past few months, several AHS members have hosted 30-minute Facebook Live events on the American Migraine Foundation’s Facebook page. Jennifer Robblee, MD, provided lifestyle-management techniques for patients with migraine. David Dodick, MD, FAHS, described...

PFO Closure for Migraine Prevention

Andrew Charles, MD, FAHS, provides an overview of the current understanding of Patent Foramen Ovale (PFOs) as it relates to patients with migraine and their risk of stroke A passageway in the heart that connects the right and left atria may be significant for some migraine patients. Patent Foramen Ovale, or PFO, is present in roughly 25% of individuals. In a recent interview, Andrew Charles, MD, Professor of Neurology at the David Geffen School of Medicine at UCLA, the Meyer and Rene Luskin Chair in Migraine and Headache Studies at UCLA and director of UCLA Goldberg Migraine Program shares why...

Concussion, Migraine and Post-Traumatic Headache

Bert Vargas, MD, discusses the similarities between migraine and post-traumatic headache One of the most debilitating symptoms a person can experience following a concussion is post-traumatic headache, says Bert Vargas, MD, an associate professor of neurology and the director of the Sports Neurology and Concussion Program at UT Southwestern Medical Center in Dallas. Post-traumatic headache occurs within seven days of concussion or regaining consciousness after concussion. Although the headache can present in many ways, it often resembles migraine in both its symptoms and duration. “This is relevant for headache providers because the majority of those post-traumatic headaches are going to...

Migraine and CBD Oil: Doctor Q&A With Stephen Silberstein, MD, FACP, FAHS

Dr. Stephen Silberstein touches on CBD oil as a potential treatment for migraine and current barriers to its use Dr. Stephen Silberstein is the director of the Headache Center at Jefferson University Hospital in Philadelphia. At the 60th Annual Scientific Meeting in San Francisco, Dr. Silberstein spoke with us about cannabidiol (CBD) and its relationship to the treatment of migraine and headache disorders. What is CBD oil, and how is it different from marijuana? Marijuana contains both tetrahydrocannabinol (THC), an active chemical that has psychoactive properties, and CBD. Unlike THC, CBD oil has no psychoactive properties and is currently on...

American Migraine Foundation Facebook Live Round Up — September

Advice from fellow AHS members In an effort to educate the patient community on the latest news and developments related to migraine and headache disorders, the American Migraine Foundation invites members of the American Headache Society to host 30-minute Facebook Live events on their Facebook page. Over the past few months, several AHS members donated their time and resources to these events. Rebecca Michael, MD, hosted an insightful talk on migraine with aura. Jennifer McVige, MA, MD, explained how she identifies headache in young patients; Lawrence Robbins, MD, spoke on how headache specialists develop treatment plans for patients; and Thomas...

Cost-Effectiveness of Erenumab for the Preventive Treatment of Episodic and Chronic Migraine

By Deena Kuruvilla, MD With the release of erenumab, the entire treatment landscape for migraine has transformed. Erenumab is a monthly injectable medication that targets the calcitonin gene-related peptide receptor for the prevention of migraine. It has been FDA approved for the prevention of episodic migraine (EM) (0-14 headache days monthly) and chronic migraine (CM) (15 or more headache days monthly). It is the first preventive medication that is specifically developed for migraine. Due to the fact that it is the first in its class, there has been major buzz about its release. It has been featured in The New...